Daiichi Sankyo Company (DSKYF) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Daiichi Sankyo (DSKYF) has updated its early cancer drug study NCT05394675, titled “A Phase 1, First-in-Human Study of DS-9606a in Patients With Tumor Types Known to Express Claudin-6 (CLDN6).” The study aimed to test safety and early signals of benefit in people with advanced or metastatic solid and germ cell tumors, a high-need area in oncology.
The treatment under review is DS-9606a, an experimental cancer drug given by intravenous infusion. It targets tumors that express Claudin-6, a marker seen in some aggressive cancers, with the goal of offering a new option where existing therapies are limited.
This is a phase 1 interventional trial with a simple structure. All patients are placed in a single treatment group, receive DS-9606a, and there is no placebo or blinding, since the main purpose is to assess safety and dose rather than direct comparison.
The study was first submitted on May 24, 2022, marking the start of regulatory tracking for this asset. The most recent update was filed on March 17, 2026, signaling a key change in status and offering investors fresh insight into Daiichi Sankyo’s early pipeline decisions.
The trial is now listed as terminated, which usually reflects safety, efficacy, or strategic portfolio reasons and can weigh on sentiment around DSKYF’s near-term pipeline value. However, the move may also free resources for better-positioned assets in oncology, while competitors in targeted cancer drugs may gain a slight relative edge in investor attention.
The study has been updated as terminated, and investors can review further details and context on the ClinicalTrials portal.
To learn more about DSKYF’s potential, visit the Daiichi Sankyo Company drug pipeline page.